Shares in many large drugmakers initially fell Wednesday on the president's threat, only to rebound later when he announced a ...

KEY TAKEAWAYS The Dow and S&P 500 wavered between gains and losses at midday Wednesday amid heightened volatility after the U ...

Trump said he would announce pharmaceutical tariffs, as he increased tariffs on China to 125% and paused tariffs for 75 ...

Goldman Sachs made significant rating changes across its U.S. biopharma coverage on Tuesday, upgrading the likes of Eli Lilly ...

Johnson & Johnson (JNJ), Merck (MRK), and Pfizer (PFE), are under pressure on Wednesday after President Trump announced that ...

The exemption may be short-lived if President Trump makes good on threats to use tariffs as leverage to bring drug production ...

Shares of drug companies including AbbVie, Eli Lilly, Pfizer and Merck were recently up 1% to 2% immediately following Trump's announcement, reversing 3% to 5% drops earlier in the day. The Dow Jones ...

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Pfizer (PFE – Research Report), with a price target of ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) had a banner year in 2024. The company's sales surged 32% to over $45 billion on massive growth from its GLP-1 agonist products, Mounjaro for ...